Axsome Therapeutics, Inc. Earnings

Axsome Therapeutics, Inc.’s revenue jumped 72.13% since last year same period to $150.04Mn in the Q2 2025. On a quarterly growth basis, Axsome Therapeutics, Inc. has generated 23.53% jump in its revenue since last 3-months.

Axsome Therapeutics, Inc.’s net profit jumped 39.54% since last year same period to $-47.97Mn in the Q2 2025. On a quarterly growth basis, Axsome Therapeutics, Inc. has generated 19.26% jump in its net profits since last 3-months.

Axsome Therapeutics, Inc.’s net profit margin jumped 64.88% since last year same period to -31.97% in the Q2 2025. On a quarterly growth basis, Axsome Therapeutics, Inc. has generated 34.63% jump in its net profit margins since last 3-months.

Axsome Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.83 - a 21.82% jump from last quarter’s estimates.

Axsome Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -0.83.

Axsome Therapeutics, Inc.’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q3 2025. This indicates that the Axsome Therapeutics, Inc. has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.